Evonik posted a 25% increase in adjusted EBITDA, reaching €2.065 billion, driven by improved profitability and cost-cutting measures. Sales remained steady at €15.2 billion, while the adjusted EBITDA margin rose to 13.6%.

Key financial highlights:

• Sales volumes grew 4%, outpacing global economic growth.
• Free cash flow increased 9% to €873 million, surpassing the company's 40% cash conversion target.
• Return on capital employed (ROCE) rose to 7.1%, compared to 3.4% in 2023.
• Dividend remains stable at €1.17 per share, offering a 6% yield.

Evonik’s efficiency program, Evonik Tailor Made, aims to cut €400 million in annual costs by 2026, while restructuring efforts streamline operations into two core segments: Custom Solutions and Advanced Technologies.

For 2025, Evonik forecasts:

• Adjusted EBITDA between €2.0 billion and €2.3 billion.
• Continued focus on bio-based solutions, energy transition, and circular economy innovations.
• Further ROCE improvement and a 40% cash conversion rate.

View detailed results here.